|
| Pimodivir Basic information |
Product Name: | Pimodivir | Synonyms: | Pimodivir;Pimodivir (VX-787);VX-787;VRT0928787;VRT-0928787;VX-787; VX 787; VX787; JNJ-872; JNJ 872; JNJ872; VRT-0928787; VRT 0928787; VRT0928787;PIMODIVIR;VX-787 (Pimodivir);Bicyclo[2.2.2]octane-2-carboxylic acid, 3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)-4-pyrimidinyl]amino]-, (2S,3S)- | CAS: | 1629869-44-8 | MF: | C20H19F2N5O2 | MW: | 399.39 | EINECS: | | Product Categories: | | Mol File: | 1629869-44-8.mol | |
| Pimodivir Chemical Properties |
density | 1.501±0.06 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | Soluble in DMSO, not in water:100.0(Max Conc. mg/mL);250.38(Max Conc. mM) | form | A solid | pka | 4.32±0.40(Predicted) | color | White to light yellow |
| Pimodivir Usage And Synthesis |
Description | Pimodivir is an inhibitor of influenza virus polymerase basic protein 2 (PB2; KD = <0.003 μM). It also binds to glycogen synthase kinase 3β (GSK3β; Ki = ~1.6 μM) and inhibits the activity of Axl and calcium/calmodulin-dependent protein kinase IIβ (CaMKIIβ) by greater than 50% in a panel of 65 human and rat kinases. Pimodivir decreases the replication of seven adamantine- and neuraminidase inhibitor-resistant strains of influenza virus A (EC50s = <0.15-2.8 nM in a cell-based assay). It increases the antiviral activity of oseltamivir , zanamivir , and favipiravir (T-705; ) with 50% combination index (CI50) values of 0.58, 0.64, and 0.89, respectively, in a cell-based assay. Pimodivir increases survival in a mouse model of intranasal influenza A infection when administered at doses of 1, 3, and 10 mg/kg twice per day. | Uses | Pimodivir is an orally bioavailable azaindole inhibitor of influenza PB2. |
| Pimodivir Preparation Products And Raw materials |
|